Cyclophosphamide, Doxorubicin, and Gemcitabine Combination Chemotherapy for Treatment of Metastatic and Locally Advanced Breast Cancer

Metastatic and locally advanced breast cancer remain a fertile field for investigation of new chemotherapeutic agents and chemotherapy combinations. We administered combination chemotherapy with cyclophosphamide, doxorubicin, and gemcitabine to 20 women with metastatic and or locally advanced breast...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 2002, Vol.20 (7-8), p.872-875
Main Authors: Levin, Mark, Durgam, Sajani, Novetsky, Allan
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Breast Neoplasms - secondary
Chemotherapy
Combined Modality Therapy
Cyclophosphamide - administration & dosage
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Doxorubicin - administration & dosage
Female
Granulocyte Colony-Stimulating Factor - administration & dosage
Humans
Medical sciences
Middle Aged
Neutropenia - chemically induced
Pharmacology. Drug treatments
Thrombocytopenia - chemically induced
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastatic and locally advanced breast cancer remain a fertile field for investigation of new chemotherapeutic agents and chemotherapy combinations. We administered combination chemotherapy with cyclophosphamide, doxorubicin, and gemcitabine to 20 women with metastatic and or locally advanced breast cancer. The regimen was well tolerated, although it required granulocyte colony stimulating factor (G-CSF) support. This novel regimen resulted in a complete response rate of 20% and overall response rates of 89% (intent-to-treat response of 80%). Gemcitabine is a highly effective agent that warrants farther evaluation as a component of multidrug chemotherapy.
ISSN:0735-7907
1532-4192
DOI:10.1081/CNV-120005898